Details for New Drug Application (NDA): 050461
NDA 050461 describes ANCEF, which is a drug marketed by Glaxosmithkline and Baxter Hlthcare and is included in three NDAs. Additional details are available on the ANCEF profile page.
The generic ingredient in ANCEF is cefazolin sodium. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
The generic ingredient in ANCEF is cefazolin sodium. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
Summary for 050461
| Tradename: | ANCEF |
| Applicant: | Glaxosmithkline |
| Ingredient: | cefazolin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050461
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
